PT3056492T - Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina) - Google Patents

Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina)

Info

Publication number: PT3056492T
Authority: PT; Portugal
Prior art keywords: megumine; delafloxacin; drug; salt; crystalline forms
Prior art date: 2004-10-08

Application number

PT151993557T

Other languages

English (en)

Original Assignee

Abbvie Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-08

Filing date

2005-10-07

Publication date

2021-12-27

2005-10-07 Application filed by Abbvie Inc filed Critical Abbvie Inc

2021-12-27 Publication of PT3056492T publication Critical patent/PT3056492T/pt

Links

DYDCPNMLZGFQTM-UHFFFAOYSA-N delafloxacin Chemical compound C1=C(F)C(N)=NC(N2C3=C(Cl)C(N4CC(O)C4)=C(F)C=C3C(=O)C(C(O)=O)=C2)=C1F DYDCPNMLZGFQTM-UHFFFAOYSA-N 0.000 title 1
229950006412 delafloxacin Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
229940079593 drug Drugs 0.000 title 1
150000003839 salts Chemical class 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C31/00—Saturated compounds having hydroxy or O-metal groups bound to acyclic carbon atoms
- C07C31/18—Polyhydroxylic acyclic alcohols
- C07C31/26—Hexahydroxylic alcohols

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Inorganic Chemistry (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

PT151993557T 2004-10-08 2005-10-07 Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina) PT3056492T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US61733404P	2004-10-08	2004-10-08

Publications (1)

Publication Number	Publication Date
PT3056492T true PT3056492T (pt)	2021-12-27

Family

ID=36129950

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT151993557T PT3056492T (pt)	2004-10-08	2005-10-07	Sal de meglumina e formas cristalinas do mesmo de um fármaco (delafloxacina)

Country Status (13)

Country	Link
US (8)	US7728143B2 (pt)
EP (3)	EP1802607A2 (pt)
CA (1)	CA2582954C (pt)
CY (1)	CY1125048T1 (pt)
DK (1)	DK3056492T3 (pt)
ES (1)	ES2901955T3 (pt)
HU (1)	HUE056718T2 (pt)
LT (1)	LT3056492T (pt)
MX (1)	MX2007004111A (pt)
PL (1)	PL3056492T3 (pt)
PT (1)	PT3056492T (pt)
SI (1)	SI3056492T1 (pt)
WO (1)	WO2006042034A2 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7576216B2 (en)	2004-07-30	2009-08-18	Abbott Laboratories	Preparation of pyridonecarboxylic acid antibacterials
ES2901955T3 (es) *	2004-10-08	2022-03-24	Abbvie Inc	Sal meglumínica y formas cristalinas de la misma de un farmaco (delafloxacina)
ATE549016T1 (de) *	2005-04-11	2012-03-15	Abbott Lab	Pharmazeutische zusammensetzungen mit verbesserten auflöseprofilen für schwerlösliche wirkstoffe
SMT202000690T1 (it)	2008-09-24	2021-01-05	Melinta Subsidiary Corp	Processo per la realizzazione di composti di chinolone
UA102709C2 (uk)	2008-11-15	2013-08-12	Ріб-Екс Фармасьютікалз, Інк.	Протимікробна композиція
BR112015021725A2 (pt) *	2013-03-08	2017-07-18	Melinta Therapeutics Inc	formas cristalinas de d-glucitol, 1-desoxi-1-(metilamino)-,1-(6-amino-3,5-difluoropiridin-2-il)-8-cloro-6-fluoro-1,4-di-hidro- 7-(3-hidroxiazetidin-1-il)-4-oxo-3-quinolinacarboxilato
CA2904387C (en)	2013-03-15	2021-12-07	Melinta Therapeutics, Inc.	Methods of treating infections in overweight and obese patients using antibiotics
TW201605447A (zh) *	2014-06-20	2016-02-16	美林塔治療學有限公司	處理感染的方法
TWI705814B (zh) *	2014-06-20	2020-10-01	美商梅琳塔有限責任公司	醫藥組成物及其用途
KR20170084200A (ko)	2014-11-14	2017-07-19	멜린타 테라퓨틱스, 인크.	피부 감염을 치료하거나, 예방하거나, 또는 그의 위험을 감소시키는 방법
CN105693695A (zh) *	2014-11-24	2016-06-22	重庆医药工业研究院有限责任公司	一种德拉沙星葡甲胺盐的晶型及其制备方法
CN106256824B (zh) *	2015-06-18	2020-10-27	重庆医药工业研究院有限责任公司	一种高纯度德拉沙星葡甲胺盐的制备方法
CN105017223B (zh) *	2015-07-08	2017-08-01	扬子江药业集团有限公司	德拉沙星葡甲胺晶型i及其制备方法
CN105017224A (zh) *	2015-07-10	2015-11-04	扬子江药业集团有限公司	一种德拉沙星葡甲胺晶型的制备方法
CN106916142A (zh) *	2015-12-25	2017-07-04	江苏奥赛康药业股份有限公司	一种制备高纯度德拉沙星的方法
CN111718331A (zh) *	2019-03-23	2020-09-29	南京海润医药有限公司	德拉沙星的杂质i和ii及产品精制方法
CN111718330A (zh) *	2019-03-23	2020-09-29	南京海润医药有限公司	一种德拉沙星杂质iii及产品精制方法
CN111718329A (zh) *	2019-03-23	2020-09-29	南京海润医药有限公司	一种德拉沙星杂质iv及产品精制方法
WO2022240897A1 (en)	2021-05-10	2022-11-17	Sepelo Therapeutics, Llc	Pharmaceutical composition comprising delafloxacin for administration into the lung
CN116514775B (zh) *	2022-01-20	2024-11-29	安徽普利药业有限公司	一种徳拉沙星葡甲胺盐新晶型及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1207994B (it) *	1986-01-03	1989-06-01	Therapicon Srl	Sali idrosulubili di composti adattivita' antiinfiammatoria ed analgesica, loro preparazione ed utilizzo in composizioni farmaceutiche.
US5578609A (en)	1994-03-25	1996-11-26	The Dupont Merck Pharmaceutical Company	2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
ATE221533T1 (de)	1994-04-12	2002-08-15	Arakis Ltd	Verfahren zur racematspaltung von etodolac unter verwendung von glucamin-derivaten
RU2171252C2 (ru) *	1995-09-22	2001-07-27	Вакунага Фармасьютикал КО., Лтд.	Аминосоединение для получения новых производных пиридонкарбоновой кислоты или их солей
EP0945134A1 (de)	1998-03-27	1999-09-29	Boehringer Ingelheim Pharma KG	Neue galenische Zubereitungsformen von Meloxicam zur oralen Applikation
JP2005097116A (ja)	1999-11-11	2005-04-14	Wakunaga Pharmaceut Co Ltd	キノリンカルボン酸誘導体アルカリ金属塩及びこれを用いたキノリンカルボン酸誘導体の精製法
GB9929037D0 (en) *	1999-12-08	2000-02-02	Glaxo Wellcome Spa	Heterocyclic derivatives
AU2700301A (en)	2000-01-31	2001-08-14	Pfizer Products Inc.	Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
JP4337283B2 (ja)	2001-07-11	2009-09-30	ソニー株式会社	光ピックアップ装置及び記録及び／又は再生装置
JP4290381B2 (ja)	2002-04-11	2009-07-01	学校法人聖マリアンナ医科大学	ピリドンカルボン酸化合物含有エマルション
JP2004168772A (ja)	2002-11-06	2004-06-17	Takeda Chem Ind Ltd	受容体調節剤
ES2901955T3 (es) *	2004-10-08	2022-03-24	Abbvie Inc	Sal meglumínica y formas cristalinas de la misma de un farmaco (delafloxacina)

2005
- 2005-10-07 ES ES15199355T patent/ES2901955T3/es not_active Expired - Lifetime
- 2005-10-07 EP EP05825344A patent/EP1802607A2/en not_active Withdrawn
- 2005-10-07 HU HUE15199355A patent/HUE056718T2/hu unknown
- 2005-10-07 LT LTEP15199355.7T patent/LT3056492T/lt unknown
- 2005-10-07 PL PL15199355T patent/PL3056492T3/pl unknown
- 2005-10-07 EP EP21196428.3A patent/EP3957632A1/en not_active Withdrawn
- 2005-10-07 DK DK15199355.7T patent/DK3056492T3/da active
- 2005-10-07 EP EP15199355.7A patent/EP3056492B1/en not_active Expired - Lifetime
- 2005-10-07 MX MX2007004111A patent/MX2007004111A/es active IP Right Grant
- 2005-10-07 PT PT151993557T patent/PT3056492T/pt unknown
- 2005-10-07 US US11/245,561 patent/US7728143B2/en active Active
- 2005-10-07 WO PCT/US2005/036024 patent/WO2006042034A2/en not_active Ceased
- 2005-10-07 SI SI200532302T patent/SI3056492T1/sl unknown
- 2005-10-09 CA CA2582954A patent/CA2582954C/en not_active Expired - Lifetime
2010
- 2010-02-05 US US12/701,254 patent/US8252813B2/en active Active
- 2010-04-20 US US12/763,476 patent/US8273892B2/en active Active
2012
- 2012-08-27 US US13/595,585 patent/US8648093B2/en not_active Expired - Lifetime
2014
- 2014-02-07 US US14/175,621 patent/US8969569B2/en not_active Expired - Lifetime
2015
- 2015-02-03 US US14/612,879 patent/US9539250B2/en not_active Expired - Lifetime
2016
- 2016-11-23 US US15/359,734 patent/US9873681B2/en not_active Expired - Lifetime
2017
- 2017-12-18 US US15/844,904 patent/US10329276B2/en not_active Expired - Lifetime
2021
- 2021-12-21 CY CY20211101121T patent/CY1125048T1/el unknown

Also Published As

Publication number	Publication date
US20100286397A1 (en)	2010-11-11
US20180105510A1 (en)	2018-04-19
ES2901955T3 (es)	2022-03-24
EP3957632A1 (en)	2022-02-23
EP3056492A1 (en)	2016-08-17
US20100261703A1 (en)	2010-10-14
US10329276B2 (en)	2019-06-25
CA2582954A1 (en)	2006-04-20
DK3056492T3 (da)	2021-12-13
US20170073329A1 (en)	2017-03-16
CY1125048T1 (el)	2023-06-09
EP1802607A2 (en)	2007-07-04
WO2006042034A2 (en)	2006-04-20
US8252813B2 (en)	2012-08-28
PL3056492T3 (pl)	2022-03-21
US9539250B2 (en)	2017-01-10
US8969569B2 (en)	2015-03-03
WO2006042034A8 (en)	2007-09-07
LT3056492T (lt)	2022-01-25
US20070043019A1 (en)	2007-02-22
JP5294633B2 (ja)	2013-09-18
US20130060040A1 (en)	2013-03-07
SI3056492T1 (sl)	2022-03-31
CA2582954C (en)	2014-07-29
US7728143B2 (en)	2010-06-01
WO2006042034A3 (en)	2006-06-22
JP2008515910A (ja)	2008-05-15
US8273892B2 (en)	2012-09-25
US20150196547A1 (en)	2015-07-16
US9873681B2 (en)	2018-01-23
US20140155380A1 (en)	2014-06-05
HUE056718T2 (hu)	2022-03-28
US8648093B2 (en)	2014-02-11
MX2007004111A (es)	2007-06-14
EP3056492B1 (en)	2021-09-22

Publication	Publication Date	Title
SI3056492T1 (sl)	2022-03-31	Sol meglumina in njene kristalinične oblike zdravila (delafloksacin)
SI1789021T1 (sl)	2012-02-29	Tabletna formulacija s podaljĹˇanim sproĹˇÄŤanjem, ki vsebuje pramipeksol ali njegovo farmacevtsko sprejemljivo sol
PL3281939T3 (pl)	2024-03-18	Kombinacja zawierająca trwały kryształ związku 4-oksochinolinowego
SI1802579T1 (sl)	2014-03-31	Derivati 3-arilaminopiridina
AP2006003768A0 (en)	2006-10-31	TetraazabenzoÄeÜazulene derivatives and analogs tehereof
ZA200708327B (en)	2009-09-30	Reduction of postoperative pain medication
PL1846566T3 (pl)	2013-08-30	Stabilne kryształy natamycyny o kształcie igiełkowatym
PL370481A1 (en)	2005-05-30	Salts of valsartan
EP1614719A4 (en)	2008-06-11	AZOVER BINDING AND SALT THEREOF
ZA200609205B (en)	2008-08-27	Crystalline forms of duloxetine free base
IL176141A0 (en)	2006-10-05	Crystalline forms of valacyclovir hydrochloride
EP1773339A4 (en)	2009-07-29	CRYSTALLINE FORM OF DONEPEZIL HYDROCHLORIDE
IL172006A0 (en)	2009-02-11	Novel crystalline forms of valacyclovir hydrochloride
EP1758664A4 (en)	2010-12-22	PROCESS USING CONTROLLED CRYSTALLIZATION TO FORM CRYSTALS OF A PHARMACEUTICAL PRODUCT
PL1802329T3 (pl)	2015-10-30	Formulacja farmaceutyczna zawierająca krystaliczną insulinę oraz rozpuszczoną insulinę
SI1631575T1 (sl)	2007-04-30	NOVI 3-DEKLADINOZIL 9a-N-KARBAMOILNI IN 9a-N-TIOKARBAMOILNI DERIVATI 9-DEOKS-9-DIHIDRO-9a-AZA-9a-HOMOERITROMICINA A
EP1885381A4 (en)	2010-07-14	PHARMACEUTICAL USE OF GRAPTOPETALUM AND RELATED PLANTS
ZA200608305B (en)	2008-08-27	Pharmaceutical composition comprising a salt of mirtazapine
PL1705998T3 (pl)	2014-10-31	Zastosowanie karboksypeptydazy
EP1744742A4 (en)	2008-04-16	CRYSTALLINE FORMS AND AMORPHOUS SODIUM EFAPROXIRAL
ZA200903645B (en)	2010-08-25	Stable S-nitrosothiols, method of synthesis and use
IL177451A0 (en)	2006-12-10	Crystalline forms of a pharmaceutical compound
PL378419A1 (pl)	2006-04-03	Kombinacja leków przeciwcukrzycowych
PL373776A1 (en)	2005-10-03	Oral pharmaceutical compound
GB2406659B (en)	2006-11-29	Medical clock